As­traZeneca CEO calls open­ing IRA drug price of­fer 'rel­a­tive­ly en­cour­ag­ing' in first char­ac­ter­i­za­tion of talks

The gov­ern­ment’s first of­fer to As­traZeneca un­der the IRA’s drug price ne­go­ti­a­tions that be­gan this month is “rel­a­tive­ly en­cour­ag­ing,” CEO Pas­cal So­ri­ot said Thurs­day, at …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER